LMB 100

Drug Profile

LMB 100

Alternative Names: RG-7787; RO 6927005

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer National Cancer Institute (USA); Roche
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Megakaryocyte potentiating factor inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Phase I Mesothelioma
  • Preclinical Solid tumours

Most Recent Events

  • 02 May 2017 LMB 100 licensed to Selecta Biosciences
  • 02 May 2017 Selecta Biosciences and the National Cancer Institute plan a phase Ib trial of LMB 100 in combination with SEL 110 for Cancer
  • 01 Apr 2017 Preclinical trials in Solid tumours in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top